Consensus for FY24 EPS is $18.51. Narrows FY24 revenue view to $4.0B-$4.1B from $4.0B-$4.2B, consensus $4.05B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
- Needham healthcare analysts hold analyst/industry conference call
- JAZZ Upcoming Earnings Report: What to Expect?
- Truist healthcare analyst holds an analyst/industry conference call
- Jazz Pharmaceuticals price target lowered to $150 from $160 at Morgan Stanley